Vivoryon Therapeutics AG (NL:VVY)
:VVY
Want to see NL:VVY full AI Analyst Report?
Top Page
Vivoryon Therapeutics AG
(VVY)
Select Model
Select Model
Rating:44Neutral
Price Target:
€1.00
▼(-31.03% Downside)
Action:Reiterated
Date:04/25/26
The score is primarily constrained by weak financial performance (no recent revenue, persistent losses, and ongoing cash burn alongside a sharply reduced equity/asset base). Technicals add further pressure with the price below key moving averages and negative MACD. Valuation contributes limited support due to a negative P/E and no dividend yield.
Positive Factors
Low Financial Leverage
Very low financial leverage reduces solvency risk and preserves strategic optionality. For a development-stage biotech, minimal debt limits near-term fixed obligations and refinancing pressure, enabling management to prioritize R&D, clinical progression or deal-making over interest servicing.
Negative Factors
Persistent Losses / No Revenue
The company remains pre-revenue with continued sizable net losses, indicating operations are not self-funding. Absent product sales, the business depends on successful trial outcomes and external capital to progress programs, lengthening the timeline to sustainable cash generation and increasing execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Financial Leverage
Very low financial leverage reduces solvency risk and preserves strategic optionality. For a development-stage biotech, minimal debt limits near-term fixed obligations and refinancing pressure, enabling management to prioritize R&D, clinical progression or deal-making over interest servicing.
Read all positive factors
Vivoryon Therapeutics AG (VVY) vs. iShares MSCI Netherlands ETF (EWN)
Market Cap
€31.98M
Dividend YieldN/A
Average Volume (3M)31.39K
Price to Earnings (P/E)―
Beta (1Y)0.64
Revenue GrowthN/A
EPS Growth58.43%
CountryNL
Employees14
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.33
Shares Outstanding29,614,338
10 Day Avg. Volume27,146
30 Day Avg. Volume31,394
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)8.11
Price to Sales (P/S)0.00
P/FCF Ratio-4.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.38
Revenue Forecast (FY)N/A
Vivoryon Therapeutics AG Business Overview & Revenue Model
Company Description
Vivoryon Therapeutics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel treatments for Alzheimer's disease. The company's therapeutic pipeline primarily focuses on mitigating Alzheimer's by targeting and...
How the Company Makes Money
Vivoryon Therapeutics AG is a clinical-stage biotechnology company and, as such, its ability to generate recurring product revenue depends on successfully developing and commercializing (or partnering to commercialize) its drug candidates; specifi...
Vivoryon Therapeutics AG Earnings Call Summary
Earnings Call Date:Sep 04, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Sep 03, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted significant clinical and financial progress, particularly in reducing expenses and advancing the varoglutamstat program, while also addressing challenges such as a reduced cash position and the need for additional financing for future studies.Positive Updates
Significant Reduction in R&D Expenses
Research and development expenses decreased by EUR 7.5 million, from EUR 10.3 million in the first half of 2024 to EUR 2.8 million in the first half of 2025, largely due to a decrease in clinical development and production costs.
Negative Updates
Decreased Cash Position
Vivoryon's cash and cash equivalents decreased to EUR 4.8 million as of June 30, 2025, from EUR 9.4 million at the end of 2024, raising concerns about future funding.
Read all updates
Q2-2025 Updates
Positive
Negative
Significant Reduction in R&D Expenses
Research and development expenses decreased by EUR 7.5 million, from EUR 10.3 million in the first half of 2024 to EUR 2.8 million in the first half of 2025, largely due to a decrease in clinical development and production costs.
Read all positive updates
Company Guidance
In the recent call discussing Vivoryon's first half 2025 results, several key metrics and achievements were highlighted. Research and development expenses for the period were EUR 2.8 million, a significant reduction from EUR 10.3 million in the first half of 2024, primarily due to decreased clinical development costs and production expenses. General and administrative expenses also saw a decline to EUR 2.8 million from EUR 3.5 million in the previous year. Consequently, the net loss for the first half of 2025 was reduced to EUR 5.5 million, compared to EUR 13.6 million in the same period of 2024. The company reported holding EUR 4.8 million in cash and cash equivalents as of June 30, 2025, with a cash runway extending into January 2026, excluding funds from a standby equity purchase agreement. Vivoryon also secured U.S. patents for varoglutamstat, ensuring market exclusivity through 2044. The company presented compelling kidney function data from its Phase II studies at the European Renal Association Annual Congress, showcasing statistically significant improvements in kidney function with varoglutamstat compared to placebo. Preparations for a dedicated Phase IIb study in diabetic kidney disease are underway, highlighting Vivoryon's strategic focus on expanding its therapeutic impact in the kidney disease market.Vivoryon Therapeutics AG Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
52
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | -3.62M | 0.00 | 10.76M |
| Gross Profit | -147.00K | -147.00K | -3.10M | -161.00K | 9.03M |
| EBITDA | -9.03M | -20.34M | -28.35M | -28.17M | -12.03M |
| Net Income | -8.85M | -20.57M | -28.34M | -28.16M | -12.65M |
Balance Sheet | |||||
| Total Assets | 7.52M | 11.28M | 30.83M | 31.38M | 24.52M |
| Cash, Cash Equivalents and Short-Term Investments | 5.62M | 9.37M | 28.58M | 26.55M | 14.66M |
| Total Debt | 108.00K | 102.00K | 38.00K | 132.00K | 224.00K |
| Total Liabilities | 2.79M | 3.40M | 4.55M | 4.87M | 7.96M |
| Stockholders Equity | 4.73M | 7.88M | 26.28M | 26.51M | 16.56M |
Cash Flow | |||||
| Free Cash Flow | -8.46M | -19.18M | -22.05M | -21.81M | -11.29M |
| Operating Cash Flow | -8.46M | -19.17M | -21.54M | -21.79M | -11.26M |
| Investing Cash Flow | -6.00K | 10.00M | -10.51M | -13.00K | -28.00K |
| Financing Cash Flow | 4.71M | -57.00K | 24.16M | 33.38M | -827.00K |
Vivoryon Therapeutics AG Peers Comparison
UnderperformOutperform
Sector (55)
NL:VVY
Vivoryon Therapeutics AG
1.08
-0.38
-26.03%
PHGUF
Pharming Group
1.30
0.23
21.50%
GB:0JXZ
Galapagos
25.74
1.89
7.93%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.